Latest filing published 14 Sept 2023 for Calidi Biotherapeutics, Inc., €4.9M.
Based on 12 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Hudson Bay Capital Management LP discloses dealings in 20 companies, chiefly Q/c Technologies, Inc., Sports Entertainment Gaming Global Corp and Chem RX Corp. In total, 58 filings cover trades dated from 3 December 2007 to 12 September 2023.
On the open market, the record shows 21 purchases worth €4.4M and 26 sales worth €24.3M. The totals exclude 4 filings filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. 2023 to date brings no purchases and 2 sales.
Half of the purchases are above €51k and half below. None of the 13 purchases we analysed coincided with buying by another insider of the same company within 30 days. Ninety days after publication, 12 purchases show a median change of +62.4%, with the price up in 100% of them. Past outcomes like these are no guarantee of what comes next.
The latest filing, published on 14 September 2023, reports a transaction of €4.9M in Calidi Biotherapeutics, Inc. The latest purchase dates back some time: it was published 1,426 days ago, on 28 November 2022. The median gap between a trade and its publication by SEC (Form 4) is 4 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 55 declarations